Cabochon Aesthetics
Scientific solutions for aesthetic procedures.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
N/A | Acquisition | ||
| Total Funding | 000k | ||
Cabochon Aesthetics, Inc. operated as a medical device company focused on developing treatments for the aesthetic market, specifically targeting cellulite. The company was established as the ninth venture from the medical device incubator, The Foundry. The CEO of the company was Ben Brian, Ph.D.
The company's core business centered on a proprietary system designed to improve the appearance of cellulite. This system, which received FDA clearance, uses a minimally invasive procedure to address the structural cause of cellulite. The technology employs a precision-guided, vacuum-assisted tool to release the fibrous septae—the connective-tissue bands that pull the skin down and create dimples. This process results in a smoother skin surface. The target clients for this technology were physician practices in the aesthetic medicine sector.
A significant milestone for Cabochon Aesthetics was securing FDA 510(k) clearance in July 2013 for its system. This clearance indicated the device for the short-term improvement in the appearance of cellulite on the buttocks and thighs of adult females. Clinical study data demonstrated considerable patient satisfaction; one year post-procedure, 94% of patients were satisfied with the results. The company's journey culminated in its acquisition by Ulthera, Inc., a global medical device company, in a deal announced in March 2014. This acquisition allowed Ulthera to enter the cellulite treatment market and expand its portfolio of aesthetic technology offerings to physicians worldwide. Prior to the acquisition, Cabochon Aesthetics had successfully raised capital, including a Series A round of $1.62M in 2005 and a Series B round of $12.1M in 2006, with total funding reported between $14.8M and $22.1M from investors like Lightstone Ventures, Morgenthaler Ventures, and Prospect Venture Partners.
Keywords: cellulite treatment, medical aesthetic devices, fibrous septae release, minimally invasive procedure, FDA-cleared aesthetic system, aesthetic dermatology, body contouring technology, vacuum-assisted tissue release, physician-administered aesthetics, The Foundry incubator, Ulthera acquisition, Ben Brian, cosmetic dermatology device, skin smoothing treatment, non-invasive fat removal, therapeutic devices, aesthetic medicine, cellulite reduction, medical device incubator, dermatological surgery